Search results for CD147

Anti-CD147 antibody [EPR18008-8], Abcam, AB188190

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

CD147 antibody (MEM-M6/1), Covalab, Ref 00113307

CD147 antibody (MEM-M6/2), Covalab, Ref 00113442

CD147 antibody (MEM-M6/6), Covalab, Ref 00113694

PE Anti-CD147 antibody [EPR4053], Abcam, AB305841

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .

Anti-CD147/BSG Antibody (R1V17), AntibodySystem, RME14002

Anti-CD147/BSG Antibody (R1V18), AntibodySystem, RHE14003

Anti-CD147/BSG Antibody (R1V19), AntibodySystem, RME14001

Anti-Human CD147/BSG Antibody (4A5), AntibodySystem, RHE14002

Anti-CD147 antibody [MEM-M6/1], Abcam, AB666

This product was changed from ascites to tissue culture supernatant on 24th January 2018. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.